Back to discover
Disease
Cholera
Late-stage therapeutic developmentEmerging researchRising momentum
4
Publications
15
Clinical trials
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Genomic insights into the 2022-2023Vibrio cholerae outbreak in Malawi.
Research2024-07-26Nature communications
The intersection between host-pathogen interactions and metabolism during Vibrio cholerae infection.
Research2024-01-11Current opinion in microbiology
Research2012-01-24Bulletin of the World Health Organization
DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae.
Research2000-08-01Nature
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 4 clinical trials expected to report results, the earliest in Q4 2026.
- 2 industry developments reported.
Upcoming Milestones
- Q4 2026Phase I/III, Multicenter, Observer-Blinded, Randomized, Active Controlled Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus in 1 to 45 Years Old South Africans
- Q1 2027A Phase II, Randomized, Controlled, Age-descending Study in Adults and Children to Evaluate the Safety and Immunogenicity of the OSP:rTTHc Cholera Conjugate Vaccine in Cholera-endemic Region
- Q2 2028A Phase IV Parallel-Group, Open-Label, Randomized Non-Inferiority Trial Evaluating Immunogenicity of Extended Dosing Intervals for Euvichol-S Oral Cholera Vaccine, Nairobi, Kenya
- Q3 2029Case-area Targeted Interventions (CATIs) Among Household Contacts and Neighbouring Households After Defining Cholera Hotspot Areas in Bangladesh: The Effectiveness of OCV and Potential Impact on Cholera Control
Major developments
Upcoming trial readoutHigh impact
Results expected Q2 20282026-03-23
Upcoming trial readoutImportant
Results expected Q3 20292026-07-06
Clinical MilestonesViewHide
Results expected
- 2026-07-06Case-area Targeted Interventions (CATIs) Among Household Contacts and Neighbouring Households After Defining Cholera Hotspot Areas in Bangladesh: The Effectiveness of OCV and Potential Impact on Cholera ControlResults expected Q3 2029
- 2026-04-03A Phase II, Randomized, Controlled, Age-descending Study in Adults and Children to Evaluate the Safety and Immunogenicity of the OSP:rTTHc Cholera Conjugate Vaccine in Cholera-endemic RegionResults expected Q1 2027
- 2026-03-23A Phase IV Parallel-Group, Open-Label, Randomized Non-Inferiority Trial Evaluating Immunogenicity of Extended Dosing Intervals for Euvichol-S Oral Cholera Vaccine, Nairobi, KenyaResults expected Q2 2028
- 2026-01-12Phase I/III, Multicenter, Observer-Blinded, Randomized, Active Controlled Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus in 1 to 45 Years Old South AfricansResults expected Q4 2026
Industry & MarketViewHide
- 2026-04-07This diet could slash cholera infections by up to 100xIndustry · Science Daily
- 2026-04-01Evolution of pandemic cholera at its global sourceIndustry · Nature News
Activity timeline6
- 2026-07-06ClinicalCase-area Targeted Interventions (CATIs) Among Household Contacts and Neighbouring Households After Defining Cholera Hotspot Areas in Bangladesh: The Effectiveness of OCV and Potential Impact on Cholera ControlResults expected Q3 2029
- 2026-04-07IndustryThis diet could slash cholera infections by up to 100xIndustry · Science Daily
- 2026-04-03ClinicalA Phase II, Randomized, Controlled, Age-descending Study in Adults and Children to Evaluate the Safety and Immunogenicity of the OSP:rTTHc Cholera Conjugate Vaccine in Cholera-endemic RegionResults expected Q1 2027
- 2026-04-01IndustryEvolution of pandemic cholera at its global sourceIndustry · Nature News
- 2026-03-23ClinicalA Phase IV Parallel-Group, Open-Label, Randomized Non-Inferiority Trial Evaluating Immunogenicity of Extended Dosing Intervals for Euvichol-S Oral Cholera Vaccine, Nairobi, KenyaResults expected Q2 2028
- 2026-01-12ClinicalPhase I/III, Multicenter, Observer-Blinded, Randomized, Active Controlled Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus in 1 to 45 Years Old South AfricansResults expected Q4 2026
Clinical trials
The current development programme across all trial phases.
Clinical programme
15
6
10
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20002024
Most influential
Major themes7
- Cholera2
- Vibrio cholerae2
- Bacteriophages1
- Chromosomes, Bacterial1
- Disease Outbreaks1
- DNA, Bacterial1
- Phylogeny1
Leading journals4
- Bulletin of the World Health Organization1
- Current opinion in microbiology1
- Nature1
- Nature communications1
Leading researchers8
- Ali M1
- Bass S1
- Bitilinyu-Bangoh J1
- Bonongwe P1
- Chaguza C1
- Chaima D1
- Chauma-Mwale A1
- Chibwe I1
Affiliations (unnormalised)6
- Balaka District Hospital1
- Department of Clinical Infection1
- Department of Clinical Sciences1
- Department of Medical Laboratory Sciences1
- International Vaccine Institute1
- Public Health Institute of Malawi1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.